Private Advisor Group LLC Buys 41,855 Shares of Codexis, Inc. (NASDAQ:CDXS)

Private Advisor Group LLC raised its holdings in shares of Codexis, Inc. (NASDAQ:CDXS) by 22.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 231,341 shares of the biotechnology company’s stock after purchasing an additional 41,855 shares during the quarter. Private Advisor Group LLC owned 0.33% of Codexis worth $807,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Opaleye Management Inc. raised its stake in shares of Codexis by 172.2% in the fourth quarter. Opaleye Management Inc. now owns 3,045,525 shares of the biotechnology company’s stock valued at $9,289,000 after acquiring an additional 1,926,625 shares during the period. GSA Capital Partners LLP raised its stake in shares of Codexis by 101.2% in the fourth quarter. GSA Capital Partners LLP now owns 837,036 shares of the biotechnology company’s stock valued at $2,553,000 after acquiring an additional 420,977 shares during the period. abrdn plc purchased a new stake in shares of Codexis in the fourth quarter valued at $490,000. Aristides Capital LLC purchased a new stake in shares of Codexis in the fourth quarter valued at $189,000. Finally, Simplex Trading LLC raised its stake in shares of Codexis by 1,444.0% in the fourth quarter. Simplex Trading LLC now owns 40,114 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 37,516 shares during the period. Institutional investors own 78.54% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Jefferies Financial Group started coverage on shares of Codexis in a research note on Monday, June 3rd. They issued a “buy” rating and a $5.00 price target on the stock. Cantor Fitzgerald assumed coverage on shares of Codexis in a report on Thursday, May 30th. They issued an “overweight” rating and a $11.00 price target on the stock. Finally, Benchmark restated a “buy” rating and issued a $9.00 price target on shares of Codexis in a report on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Codexis currently has a consensus rating of “Moderate Buy” and an average target price of $7.14.

Codexis Stock Down 1.8 %

CDXS opened at $3.20 on Friday. Codexis, Inc. has a twelve month low of $1.45 and a twelve month high of $4.91. The company has a quick ratio of 3.63, a current ratio of 3.71 and a debt-to-equity ratio of 0.35. The company has a 50-day moving average price of $3.24 and a 200 day moving average price of $3.17. The company has a market cap of $225.79 million, a PE ratio of -3.44 and a beta of 2.12.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. Codexis had a negative net margin of 87.73% and a negative return on equity of 41.76%. The company had revenue of $17.07 million during the quarter, compared to analysts’ expectations of $14.06 million. Sell-side analysts expect that Codexis, Inc. will post -0.63 earnings per share for the current fiscal year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.